DLL1 and breast cancer: Thus, Kumar and coworkers showed that DLL1, but not other NOTCH ligands (DLL3, JAGGED1, and JAGGED 3), is overexpressed in ER+ luminal breast cancers: in these tumors, DLL1 overexpression correlates with poor prognosis [392].